DCTs can be a great tool for small-to-midsize pharma and biotech companies despite misconceptions of them being advantageous for only Big Pharma.
Kristin Mauri
Advertisement
Solutions Services Director, Remarque Systems
Articles by Kristin Mauri
Researchers aren't taking full advantage of advances in trial technologies. A lack of clarity in the current version of the International Council for Harmonization "Guidelines for Good Clinical Practice", could be the problem.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
How to recruit specialty volunteer populations for early-phase clinical research: 5 things to ask when choosing a CRO partner
2
Sponsor Oversight in an Outsourced Trial: What Good Looks Like and How to Evidence It
3
How AI Is Changing Endpoint Selection Before a Trial Even Starts
4
ACT Brief: Patient-Site Trust Barriers, Rare Disease Evidence Without Registry, and RWD Enrollment Accuracy
5